膜性狼疮肾炎中EXT1/EXT2阳性与阴性代表两种不同表型
本研究在374例经活检证实的膜性狼疮肾炎患者中,通过免疫组化检测EXT1/EXT2表达,发现32.6%为阳性。EXT1/EXT2阳性患者更年轻、血肌酐更低、蛋白尿≥3.5 g/24h更常见,且慢性化病变更少;阴性患者进展至ESKD的比例显著更高(18.8% vs 3.1%,P=0.003)。
要点
- 膜性狼疮肾炎中EXT1/EXT2阳性率32.6%。
- EXT1/EXT2阳性者临床病理更轻,慢性化指标更少。
- EXT1/EXT2阴性者进展至ESKD风险更高(18.8% vs 3.1%)。
核心结论
- EXT1/EXT2阳性膜性狼疮肾炎患者肾脏活检慢性化指数更有利,阴性患者更易进展至ESKD。
研究设计与样本
- 回顾性队列研究,纳入374例经活检证实的膜性狼疮肾炎患者,对肾活检标本进行EXT1和EXT2免疫组化检测,比较阳性与阴性患者的临床病理特征及结局。
主要发现
- 122例(32.6%)为EXT1/EXT2阳性,252例(67.4%)为阴性。
- EXT1/EXT2阳性患者显著更年轻(P=0.01),血清肌酐显著更低(P=0.02)。
- EXT1/EXT2阳性患者蛋白尿≥3.5 g/24h的比例显著更高(P=0.009)。
- EXT1/EXT2阳性患者肾小球硬化(P=0.001)和间质纤维化及肾小管萎缩(P<0.001)显著更少。
- 160例有随访数据,其中64例(40%)EXT1/EXT2阳性,96例(60%)阴性;阴性组进展至ESKD比例显著更高(18.8% vs 3.1%,P=0.003)。
关键数值与推荐
- EXT1/EXT2阳性率32.6%(122/374)。
- EXT1/EXT2阳性与阴性组中,合并class 3/4狼疮肾炎的比例无差异(25.0% vs 32.3%;P=0.32)。
临床怎么用
- 对膜性狼疮肾炎患者进行EXT1/EXT2免疫组化检测可能有助于风险分层,阳性者肾脏慢性化病变较轻,阴性者需更密切监测肾功能进展。
局限性
- 回顾性研究设计,仅160例有临床随访数据,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In patients with secondary (autoimmune) membranous nephropathy, two novel proteins, Exostosin 1 and Exostosin 2 (EXT1/EXT2), are potential disease antigens, biomarkers, or both. In this study, we validate the EXT1/EXT2 findings in a large cohort of membranous lupus nephritis. METHODS: We conducted a retrospective cohort study of patients with membranous lupus nephritis, and performed immunohistochemistry studies on the kidney biopsy specimens against EXT1 and EXT2. Clinicopathologic features and outcomes of EXT1/EXT2-positive versus EXT1/EXT2-negative patients were compared. RESULTS: Our study cohort included 374 biopsy-proven membranous lupus nephritis cases, of which 122 (32.6%) were EXT1/EXT2-positive and 252 (67.4%) were EXT1/EXT2-negative. EXT1/EXT2-positive patients were significantly younger (P=0.01), had significantly lower serum creatinine levels (P=0.02), were significantly more likely to present with proteinuria ≥3.5 g/24 h (P=0.009), and had significantly less chronicity features (glomerulosclerosis, P=0.001 or interstitial fibrosis and tubular atrophy, P<0.001) on kidney biopsy. Clinical follow-up data were available for 160 patients, of which 64 (40%) biopsy results were EXT1/EXT2-positive and 96 (60%) were EXT1/EXT2-negative. The proportion of patients with class 3/4 lupus nephritis coexisting with membranous lupus nephritis was not different between the EXT1/EXT2-positive and EXT1/EXT2-negative groups (25.0% versus 32.3%; P=0.32). The patients who were EXT1/EXT2-negative evolved to ESKD faster and more frequently compared with EXT1/EXT2-positive patients (18.8% versus 3.1%; P=0.003). CONCLUSIONS: The prevalence of EXT1/EXT2 positivity was 32.6% in our cohort of membranous lupus nephritis. Compared with EXT1/EXT2-negative membranous lupus nephritis, EXT1/EXT2-positive disease appears to represent a subgroup with favorable kidney biopsy findings with respect to chronicity indices. Cases of membranous lupus nephritis that are EXT1/EXT2-negative are more likely to progress to ESKD compared with those that are EXT1/EXT2-positive.
引用
- Ravindran A, Casal Moura M, Fervenza FC, et al. In Patients with Membranous Lupus Nephritis, Exostosin-Positivity and Exostosin-Negativity Represent Two Different Phenotypes. J Am Soc Nephrol. 2021. PMID: 33478971. doi:10.1681/ASN.2020081181
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。